Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis

Ursula McGivern, Darren M Mitchell, Cliona McDowell, Jolyne O'Hare, Gemma Corey, Joe M O'Sullivan

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

The purpose of this study was to compare the prostate-specific antigen (PSA) response to either neoadjuvant bicalutamide (BC) monotherapy or neoadjuvant luteinizing hormone-releasing hormone agonist (LHRHa) monotherapy and the subsequent effect on biochemical failure-free survival (BFFS) in men receiving radical radiotherapy (RT) for localized prostate cancer.
Original languageEnglish
Pages (from-to)190-5
Number of pages6
JournalClinical genitourinary cancer
Volume10
Issue number3
DOIs
Publication statusPublished - Sep 2012

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis'. Together they form a unique fingerprint.

Cite this